1-2 of 2
Enrique Baez De La Fuente, MD
Close
Sort by
Journal Articles

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Lynda Foltz, MD FRCPC, Gian-Matteo Pica, MD, Hacene Zerazhi, Jan Van Droogenbroeck, MD, Sorin Visanica, MD, Enrique Báez de la Fuente, MD, Brian Leber, MD, Antonio Medina de Almeida, MD PhD, Dana Ranta, MD, Mauricio Reyes Cartes, MD, Jean-Jacques Kiladjian, MD PhD, Linda Chrit, PhD, Zhaoyu Yin, PhD, Juliane Morando, MD, Timothy Devos
Journal: Blood
Blood (2018) 132 (Supplement 1): 1774.
https://doi.org/10.1182/blood-2018-99-111479
Published: 2018
Journal Articles

Can the Autologous Transplant of Hematopoyetic Progenitors be Considered an Effective Alternative to Increase Global Survival in High-Grade Non-Hodgkin Lymphomas?

Alba Nydia Ramirez Lopez, MD, Enrique Baez De La Fuente, MD, Rosa Elva De Leon Cantu, MD, Diego Cruz Contreras, MD, Jose Alfredo Carrizalez Villarreal, MD, Jose Luis Cedillo De La Cerda, Roxana Saldaña Vazquez, MD, Helga Patricia Sorkee Davila, MD, Axel Eduardo Rosas Rodríguez, MD, Severiano Baltazar Arellano, MD, Roberto Hernandez Valdes, MD, Bernardo Lafarga Amao, RESIDENTE, Rosa Lozano, MD, Andrea Terrazas, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5520.
https://doi.org/10.1182/blood.V130.Suppl_1.5520.5520
Published: 2017